Literature DB >> 11691818

Absence of genetic abnormalities in fibroadenomas of the breast determined at p53 gene mutations and microsatellite alterations.

N Franco1, S F Picard, F Mege, L Arnould, S Lizard-Nacol.   

Abstract

Genesis of breast cancer is a multistage process involving accumulation of genetic alterations, but little is known about the implication of genetic alterations in benign breast disease (BBD) lesions. Among benign lesions of the breast, one of the most common is fibroadenoma. The relationship between fibroadenoma and breast cancer is not clear. Some epidemiological studies show an association with breast cancer risk, whereas recent reports show no increased risk. In a previous study, we analyzed genetic alterations in a group of BBD lesions composed namely of fibroadenomas unaffected by breast cancer, and we found no evident implication of several loci by Southern blot method. However, genetic alterations, including p53 gene mutations, loss of heterozygosity, microsatellite instability, and cytogenetic chromosomal aberrations, have been reported recently to occur in fibroadenomas. Thus, we reexamined our BBD population for p53 gene mutations and for microsatellite alterations with 13 markers using a PCR-based method. Our results show that no molecular alterations were detected in these BBD lesions composed namely of fibroadenomas unaffected by breast cancer. Neither p53 gene mutations, determined at exons 5-9, nor microsatellite alterations tested with a very sensitive method were found in these lesions. Therefore, molecular results obtained in our study support recent epidemiological data showing that fibroadenoma does not constitute a significant increase in the relative risk of later contracting breast cancer.

Entities:  

Mesh:

Year:  2001        PMID: 11691818

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  4 in total

1.  Exome sequencing identifies highly recurrent MED12 somatic mutations in breast fibroadenoma.

Authors:  Weng Khong Lim; Choon Kiat Ong; Jing Tan; Aye Aye Thike; Cedric Chuan Young Ng; Vikneswari Rajasegaran; Swe Swe Myint; Sanjanaa Nagarajan; Nur Diyana Md Nasir; John R McPherson; Ioana Cutcutache; Gregory Poore; Su Ting Tay; Wei Siong Ooi; Veronique Kiak Mien Tan; Mikael Hartman; Kong Wee Ong; Benita K T Tan; Steven G Rozen; Puay Hoon Tan; Patrick Tan; Bin Tean Teh
Journal:  Nat Genet       Date:  2014-07-20       Impact factor: 38.330

2.  Analysis of human mammary fibroadenoma by Ki-67 index in the follicular and luteal phases of menstrual cycle.

Authors:  M F Rego; M A L H Navarrete; G Facina; R Falzoni; R Silva; E C Baracat; A C P Nazario
Journal:  Cell Prolif       Date:  2009-04       Impact factor: 6.831

3.  The genomic mutation spectrums of breast fibroadenomas in Chinese population by whole exome sequencing analysis.

Authors:  Shang-Nao Xie; Yuan-Jie Cai; Bo Ma; Yanting Xu; Peng Qian; Juan-Di Zhou; Fu-Guang Zhao; Jie Chen
Journal:  Cancer Med       Date:  2019-03-09       Impact factor: 4.452

4.  Droplet-digital PCR reveals frequent mutations in TERT promoter region in breast fibroadenomas and phyllodes tumours, irrespective of the presence of MED12 mutations.

Authors:  Kazutaka Otsuji; Takeshi Sasaki; Masahiko Tanabe; Yasuyuki Seto
Journal:  Br J Cancer       Date:  2020-10-13       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.